Epithelial ovarian cancer (EOC) is the deadliest gynecologic cancer. Recently, the existence of ovarian cancer stem cells has been reported. Sox2, Nanog and Oct4 are key markers of "stemness". The objective of this study was to determine whether Sox2, Nanog, and Oct4 are associated with EOC and poor outcome. The expression of these markers was assessed by immunofluorescence staining and real-time RT-PCR in human EOC cell lines MDAH-2774 and SKOV-3, while the cancer genome atlas (TCGA) dataset was analyzed for associations with survival. Sox2, Nanog and Oct4 (POU5F1) were all detected by immunofluorescence staining and these results were confirmed by real-time RT-PCR. The TCGA dataset revealed a 26%, 9%, and 6% amplification of Sox2, Nanog and POU5F1, respectively. Additionally, K-M survival analyses showed a significant median overall survival difference (41 versus 48.3 months, P =.01) for Sox2 amplification, but not for Nanog (44.1 versus 36.2 months, P >.05) and POU5F1 (43.5 versus 45.0 months, P >.05). Our results suggest that Sox2 gene amplification significantly influences overall survival.
- Sox2 amplification
- overall survival
- serous epithelial ovarian cancer
ASJC Scopus subject areas
- Obstetrics and Gynecology